Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at Citigroup Inc. from $4.00 to $3.50. They now have a "neutral" rating on the stock.
Ovid Therapeutics Inc. (NASDAQ: OVID) is now covered by analysts at B. Riley. They set a "buy" rating and a $9.00 price target on the stock.
Ovid Therapeutics Inc. (NASDAQ: OVID) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth [Yahoo! Finance]